Sudden cardiac arrest in hemodialysis patients with wearable cardioverter defibrillator
Related Experiment Video
Updated: May 5, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Chingping Wan1, Charles A Herzog, Wojciech Zareba
1Clinical Research, ZOLL, Pittsburgh, PA.
Insights
Sudden cardiac arrest (SCA) survival is poor for hemodialysis (HD) patients. Wearable cardioverter defibrillators (WCDs) in HD patients showed improved post-SCA survival compared to historical data.
Area of Science:
- Cardiology
- Nephrology
- Medical Devices
Background:
- Sudden cardiac arrest (SCA) survival outcomes are poor for hemodialysis (HD) patients.
- Characteristics of SCA and survival post-event in HD patients using wearable cardioverter defibrillators (WCDs) are not well understood.
Purpose of the Study:
- To investigate the characteristics of SCA events in HD patients using WCDs.
- To evaluate the post-SCA survival rates in HD patients treated with WCDs.
Main Methods:
- Retrospective study of HD patients prescribed WCDs between 2004-2011 who experienced SCA.
- Data collected on demographics, clinical background, and SCA event characteristics from manufacturer database.
- Mortality determined using the Social Security Death Index.
Main Results:
- 84 SCA events in 75 HD patients (mean age 62.9 years); 78.6% due to ventricular tachycardia/fibrillation.
- Acute 24-hour survival was 70.7%, 30-day survival was 50.7%, and 1-year survival was 31.4%.
- Women demonstrated significantly better post-SCA survival than men (HR=2.41, P=0.03).
Conclusions:
- The use of WCDs in HD patients is associated with improved post-SCA survival.
- Findings suggest WCDs may be a valuable tool for managing SCA risk in this population.
Background:
The survival outcome following a sudden cardiac arrest (SCA) in hemodialysis (HD) patients is poor regardless of whether an event takes place in or out of a dialysis center. The characteristics of SCA and post-SCA survival with HD patients using a wearable cardioverter defibrillator (WCD) are unknown.
Methods:
All HD patients who were prescribed a WCD between 2004 and 2011 and experienced at least one SCA event were included in this study. Demographics, clinical background, characteristics of SCA events were identified from the manufacturer's database. An SCA event was defined as all sustained ventricular tachycardia/fibrillation (VT/VF) or asystole occurring within 24 hours of the index arrhythmia episode. The social security death index was used to determine mortality after WCD use.
Results:
A total of 75 HD patients (mean age = 62.9 ± 11.7 years, female = 37.3%) experienced 84 SCA events (119 arrhythmia episodes) while wearing the WCD. Sixty six (78.6%) SCA events were due to VT/VF and 18 (21.4%) were due to asystole. Most SCA episodes occurred between 09:00 and 10:00 (RR = 2.82, 95% CI [1.05, 7.62], P < 0.0001), followed by the 13:00-14:00 time interval (RR = 2.22, 95% CI [0.79, 6.21], P = 0.006). Acute 24-hour survival was 70.7% for all SCA events; 30-day and 1-year survival were 50.7% and 31.4%, respectively. Women had a better post-SCA survival than men (HR = 2.41, 95% CI [1.09, 5.36], P = 0.03).
Conclusions:
The use of WCD in HD patients was associated with improved post-SCA survival when compared to historical data.
More Related Videos
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
16:40A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Related Concept Videos
Cardiopulmonary Resuscitation III: AED Use
Hemodialysis II: Procedure and Complications
Continuous Renal Replacement Therapy
Hemodialysis I: Introduction
Cardiac Catheterization I: Pre-Procedure Overview
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy